Potenial Cancer Treatment With Major Catalysts On The Horizon

Cancer remains a devastating scourge that affects approximately 39.5% of the global population at some point in their lifetime1

According to the National Cancer Institute, approximately 18 million  people are diagnosed with cancer each year2.

Despite this, the main therapies used to treat cancer, are now more than 80 years old, with chemotherapy first becoming widely used in the 1940s,3 and radiation dating as far back as 18954.

Yet that appears to be changing rapidly, as a new class of immuno-oncology companies look to the body’s own natural defense system, NK cells.

A Burgeoning Immuno-Oncology Industry

According to a Research and Markets report, there are around 100 companies and 140 new drug therapies in the Natural Killer Cell pipeline landscape.5 Many of which are already seeing staggering growth, as the sector quickly gains widespread attention.

Unfortunately, many of the stocks in this sector have already seen huge growth – and are now selling at a premium. 

That’s why investors are taking a close look at companies just coming online with newer, more effective treatments. And one upstart is just starting to gain widespread attention.

This company is an attractive target because it’s a small company with transformative potential, and its still flying under the radar of Wall Street.

What sets this newcomer apart is its proprietary protein technology.

Originally developed by renowned immunologist, Dr. Jeffrey Miller of the University of Minnesota Medical School, it works by activating a special type of white blood cell, helping it identify and eliminate cancer cells in the body. 

The proteins, delivered to a patient intravenously6, are designed to trigger a “marker” on a patient’s tumor cells and then tell NK cells in the patient’s body to attack the marked cells.

Unlike some conventional chemotherapy treatments, which often attack both healthy cells along with cancer cells, this company’s agents are designed for precision, programming NK cells to attack only tumor cells and to leave healthy cells intact. 

This helps to reduce the body’s own, often debilitating immune system response that happens when cancer cells are attacked.

There are two main types of cancer-fighting lymphocyte (white blood) cells in a human body:  T-cells and NK cells.

The T-Cells are like ordinary infantry soldiers.  They can attack tumor cells and may or may not win any given battle.  The problem with T-cells is that, if you get too many of them fighting all at once, they can cause destruction in their own right – what doctors call a “cytokine storm”.

Most biotech companies working in the field are trying to harness the power of the NK cells.  The problem is, there aren’t as many NK cells in the body as T-cells – and once their primary target is destroyed, they’re exhausted and cease fighting. 

As a result, many biotech companies developing immunotherapy treatments for cancer try to create new NK cells in a lab.  But this is a time-consuming process that is hugely expensive and often very hard on patients.

Based on Dr. Miller’s latest breakthrough, this company is working towards a radically new approach.

This companies “secret sauce” is the unique way it is able to embed a compound known as interleukin (IL-15) within its protein at 17 times7 the normal dose and yet without side effects. 

This potent blast of interleukin acts like a kind of cellular steroid, greatly prolonging the  ability of the NK cells and helping them to proliferate.

The bottom line is that this is potentially a revolutionary breakthrough and, if it works, the size of the market is enormous. 

Data from early clinical trials are encouraging.  

Plus, the cost is low:  Just $30,000 per patient (covered by many insurance policies) instead of the $2 to $3 million per patient that other NK cell immunotherapies can charge.

For investors, there’s something else: The protein is a genuinely new “first in class” approach that makes this company stand out from its competitors, even those with market caps in the billions. 

A Small Company with a Breakthrough Technology

Most important for investors, the market cap of other NK cell immunotherapy companies are in the billions.

In contrast, the company we are discussing is a smaller company that has licensed and is developing Dr. Miller’s latest, most advanced immunotherapy – and so its market cap is only $300 million and growing fast.

That means early investors can acquire significant share positions at very low costs.  If clinical trials of this companies’ therapies show further promise, then all bets are off. 

Of course, it goes without saying that there are no guarantees in biotech investing.  Past performance is no guarantee of future results, and you should only speculate with money you can afford to lose.

Yet for investors who like stocks with a substantial risk/ reward ratio, then this company, currently selling for less than $10 per share, may well be worth a close look.  Sign up to learn more about this fast-developing opportunity.

[optin-monster slug="p5ms6hfkfa44rdacnswq"]

6  Verify
7  Webinar video, Minute 12:00 ff.

Legal Notice: This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any company or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled company’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.